Loading
A Bangladeshi medicines maker founded in 1999 that says it exports to more than 102 countries, and that has tested its own version of the breast cancer antibody trastuzumab against the Roche original.
Incepta Pharmaceuticals describes itself as a pharmaceutical company in Bangladesh established in 1999, with manufacturing at Savar and Dhamrai outside Dhaka and a head office in Tejgaon, and states that it is currently exporting to more than 102 countries. Its divisions include vaccines and biotechnology.
It sponsored a randomised, double-blind phase 1 study (NCT06886659) comparing the pharmacokinetics, immunogenicity and safety of its proposed trastuzumab biosimilar with Roche's trastuzumab (Herclon, the reference product named in the registry) after a single 6 mg/kg infusion in 80 healthy adults at two Dhaka sites; the registry records it as completed, from 23 January 2024 to 28 December 2024, with no results posted. The study is an example of the domestic industry the Directorate General of Drug Administration describes as now making anti-cancer medicines locally.
The first targeted antibody for a solid tumour (1998), which turned HER2-positive breast cancer from the worst subtype into one of the most treatable.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/